Biotricity Inc. (BTCY): Total Assets
$6.45M
As of 2026-03-31
$6.02M
As of 2026-06-30
-0.3%
3-year compound annual growth
+7.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $6.45M | +14.3% | 2026-07-14, Balance as of period end |
| 2025-03-31 | $5.64M | -5.1% | 2026-07-14, Balance as of period end |
| 2024-03-31 | $5.94M | -8.7% | 2025-07-18, Balance as of period end |
| 2023-03-31 | $6.51M | -61.0% | 2024-06-27, Balance as of period end |
| 2022-03-31 | $16.68M | +275.8% | 2023-06-29, Balance as of period end |
| 2021-03-31 | $4.44M | +121.4% | 2022-07-14, Balance as of period end |
| 2020-03-31 | $2.00M | +308.5% | 2021-06-22, Balance as of period end |
| 2019-03-31 | $490.7K | -47.2% | 2020-07-15, Balance as of period end |
| 2018-03-31 | $929.4K | +96.3% | 2019-07-16, Balance as of period end |
| 2017-03-31 | $473.5K | n/a | 2018-07-13, Balance as of period end |
| 2016-12-31 | $67.5K | -87.0% | 2017-03-30, Balance as of period end |
| 2015-12-31 | $519.1K | n/a | 2017-03-30, Balance as of period end |
| 2015-08-31 | $18.7K | n/a | 2016-04-13, Balance as of period end |
| 2014-08-31 | $0 | n/a | 2015-11-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Biotricity Inc. (BTCY) | 2026-03-31 | $6.45M | +14.3% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $77.47M | +10.3% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $15.77M | -51.9% |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $25.15M | +64.6% |
| Nephros Inc (NEPH) | 2025-12-31 | $13.64M | +21.7% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $13.96M | +1.9% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | $21.41M | +77.0% |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $110.08M | -7.4% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $10.46M | -4.8% |
Compare BTCY, PROF, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗